Reason for request
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
he1Zaz1LP4EdS1G1
